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A commentary on
The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial
hypertension
by Chen, J., Tang, H., Sysol, J. R., Moreno-Vinasco, L., Shioura, K. M., Chen, T., et al. (2014). Am. J.
Respir. Crit. Care Med. 190, 1032–1043. doi: 10.1164/rccm.201401-0121OC
Pulmonary arterial hypertension (PAH) is a progressive and irreversible lung disease that reduces
survival. Importantly, the pulmonary arteries carry blood from the heart to the lungs; however, in
PAH pulmonary vessels are remodeled causing abnormal constriction and a pressure change that
prevents an adequate supply of oxygen delivered to the lung tissue (Farber and Loscalzo, 2004).
PAH is categorized as a pulmonary artery pressure greater than 25mmHg, with various factors
contributing to the pathogenesis of the disease, including higher levels of endothelin-1, decreased
nitric oxide (NO) synthase expression, and inhibition of the prostacyclin pathway which leads to
decreased relaxation and induced proliferation of pulmonary artery smoothmuscle cells (PASMCs)
(McLaughlin and McGoon, 2006). Inflammation, toxins, lack of oxygen, and the deregulation
of coagulation factors, are associated with endothelial cell dysfunction in PAH (McLaughlin and
McGoon, 2006). The main pathologic changes associated with PAH include vasoconstriction,
endothelial and smooth-muscle cell proliferation, thrombosis, and pulmonary remodeling (Farber
and Loscalzo, 2004). PAH may eventually cause an enlarged right ventricle and compressed left
side of the heart, leading to right ventricular heart failure in severe cases (McLaughlin andMcGoon,
2006). It has also been theorized that glycolysis and oxidative phosphorylation play a role in patients
with PAH, mediating cell proliferation, migration, and angiogenesis (Chen et al., 2014). Individuals
aﬄicted with PAH have dyspnea, angina, fatigue, and increased pulmonary resistance (McLaughlin
and McGoon, 2006). Without medical treatment, the survival rate is estimated to be less than 3
years after diagnosis (Cottrill and Chan, 2013). Thus, PAH is a serious illness and can be fatal,
which signifies the importance of finding novel targets that can control and regulate this disease
(Beckham et al., 2013; Chen et al., 2014).
Although current treatment options for PAH include phosphodiesterase-5 inhibitors,
prostanoids, calcium channel blockers, endothelin receptor antagonists, diuretics, oxygen therapy,
and surgical procedures, such as atrial septostomy, these treatments only delay the progression of
the disease (McLaughlin and McGoon, 2006; Tuder et al., 2012). Thus, a cure for PAH remains
to be elucidated. Interestingly, recent research suggests that two important kinases, sphingosine
kinase 1 (SphK1) and sphingosine kinase 2 (SphK2), are primary therapeutic targets for pulmonary
hypertension (Cottrill and Chan, 2013; Chen et al., 2014). It is reported that SphK1 is a promoter
for tumor progression, invasion, and metastasis in gastric, prostate, colon, breast, and small cell
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FIGURE 1 | Mechanistic pathway of SphK1 and S1P. Exposure to hypoxia
induces an upregulation of SphK1, which phosphorylates sphingosine and
produces spingosine-1-phosphate (S1P). Higher concentrations of S1P will
induce cell proliferation, tissue inflammation, cell motility, and cell survival.
These responses promote the progression of pulmonary arterial hypertension
(PAH). S1P can also be cleaved by S1P lyase, generating the stable
non-sphingolipid products ethanolamine-1-phosphate and palmitaldehyde.
lung cancers (Beckham et al., 2013; Yang et al., 2014).
Overexpression of SphK1 is known to stimulate the production
of various cell types, such as NIH 3T3 fibroblasts, intestinal
epithelial cells, and endothelial cells (Chen et al., 2014). A
study by Chen and his colleagues showed that SphK1 and
SphK2 regulate phosphorylation, and therefore synthesis of
sphingosine-1-phosphate (S1P), a bioactive sphingolipid that
mediates the lipid bilayer and promotes cell proliferation,
migration, and angiogenesis (Chen et al., 2014). Additionally,
SphK1 is the most prevalent form of the two kinases and is found
in the lungs, kidneys, blood and spleen (Chen et al., 2014).
In a recent study, Chen et al. (2014) provides experimental
evidence suggesting that SphK1/S1P signaling may be a
promising therapeutic pathway to treat PAH (Figure 1). Chen
et al. (2014) investigated the pathway in two experimental
models: mice and rats (rodents) with hypoxia-induced PH and
patients with idiopathic PAH. The results show that expression
levels of SphK1 and S1P were considerably higher in the lungs
of patients with PAH and in PH rodent models after exposure
to hypoxia (10% O2) for 4 weeks, compared to normoxic
control animals. Immunoblot analysis validated elevated SphK1
and SphK2 protein levels, with β-actin acting as a control to
indicate the increase in activity of both proteins. However, SphK2
expression was not changed when compared to the normoxic
controls. SphK1 and S1P levels, measured by C18-S1P, were also
elevated in the lung tissue and pulmonary arteries isolated from
rodent models. Inhibition of SphK1 reduced cell proliferation
and pathological indications of vascular remodeling in vivo,
suggesting the role of SphK1 in causing pulmonary hypertension.
Chen et al. (2014) also compared S1P lyase (Sgpl1)-
deficient mice exposed to hypoxia to wild-type Sgp1 mice to
examine whether increased levels of S1P contributes to the
pathogenesis of PH. Sgpl1-deficient mice showed increased
expression of S1P in both normoxia and hypoxia conditions.
After a 6-week hypoxia exposure, elevated right ventricular
systolic pressure (RVSP) and pulmonary vascular remodeling
developed in Sgpl1-deficient mice; however, these outcomes
were not observed in wild-type mice. Furthermore, Chen et al.
(2014) showed that the SphK1/S1P pathway is dependent on
ligation to the sphinogosine-1-phosphate receptor 2 (S1PR2) in
human pulmonary arterial smooth muscle cells (PASMCs), after
expression of S1PR2 was confirmed. Inhibition of S1PR2 by
JTE013 antagonist further confirmed the ligation process of the
SphK1/S1P pathway.
Chen et al. (2014) demonstrated that uncontrolled PASMC
cell reproduction and its resistance to apoptosis are main
components of the PAH mechanistic pathway. Additionally, the
results show that S1P promoted PASMC cell proliferation is
dose-dependent and plays a major role in pulmonary vascular
remodeling evident in PAH. Taken together, Chen et al. (2014)
and his colleagues produced significant evidence to show that
Sphk1 is associated with the pathophysiology of PAH. These
findings are significant because they provide a foundation on
which to base further research in order to treat patients with
PAH. Experimental evidence demonstrates that at the cellular
level, PAH and hypoxia-induced PH is caused by multiple factors
(Cottrill and Chan, 2013). Chen et al. (2014) also demonstrated
that S1P regulates PASMC proliferation and regulates the
expression of proapoptotic and antiapoptotic proteins (Chen
et al., 2014). Consequently, altering the metabolic pathway of
SphK1/S1P may serve as an alternative approach to ameliorate
the progression of PAH (Chalfant and Spiegel, 2005; Tuder et al.,
2012; Beckham et al., 2013). These results indicate that the
SphkK1/S1P pathway promotes PASMC cell proliferation and
pulmonary remodeling, suggesting that SphK1, S1P, and S1PR2
are future therapeutic targets for the treatment of PAH.
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